guanabenz has been researched along with Hypertrophy, Left Ventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akutsu, M; Jin, EZ; Kakinoki, S; Katoh, K; Kitabatake, A; Nomura, A; Shimono, H; Takechi, S | 1 |
| Endo, T; Hishiki, S; Kawano, Y; Miyajima, E; Shigemasa, T | 1 |
2 other study(ies) available for guanabenz and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Recovery of cardiac norepinephrine concentration and tyrosine hydroxylase activity by the central alpha2-adrenoceptor agonist guanabenz in rats with aortic constriction.
Topics: Adrenal Glands; Adrenergic alpha-Agonists; Animals; Aorta, Thoracic; Body Weight; Constriction; Guanabenz; Heart; Heart Ventricles; Hypertrophy, Left Ventricular; Kidney; Liver; Male; Methoxyhydroxyphenylglycol; Myocardium; Norepinephrine; Organ Size; Rats; Rats, Wistar; Spleen; Tyrosine 3-Monooxygenase; Vas Deferens | 1999 |
Guanabenz combination therapy inhibits sympathetic nerve activity and regresses left ventricular hypertrophy.
Topics: Antihypertensive Agents; Blood Pressure; Drug Therapy, Combination; Female; Guanabenz; Heart Rate; Humans; Hypertension; Hypertrophy, Left Ventricular; Male; Middle Aged; Norepinephrine; Organ Size; Sympathetic Nervous System; Sympatholytics | 2000 |